Home/Zymeworks/Kristin Stafford
KS

Kristin Stafford

Chief Financial Officer (as of April 2026)

Zymeworks

Therapeutic Areas

Zymeworks Pipeline

DrugIndicationPhase
Ziihera® (zanidatamab)Biliary tract cancers, HER2+ solid tumorsApproved
PasritamigGastrointestinal stromal tumor (GIST)Phase 2/3
ZW191Ovarian cancer, Endometrial cancer, Non-small cell lung cancerPhase 1
ZW251Hepatocellular carcinoma (HCC)Phase 1
ZW220Ovarian cancer, NSCLC, Pancreatic cancerPreclinical
ZW209DLL3-expressing cancersPreclinical
ZW1528Mixed-type COPDPreclinical